Abbott unveils AVEIR DR leadless pacemaker system with CE Mark approval in Europe

Abbott unveils AVEIR DR leadless pacemaker system with CE Mark approval in Europe

Abbott has achieved a significant milestone in cardiac healthcare by securing the CE Mark for its AVEIR dual chamber (DR) leadless pacemaker system in Europe. This groundbreaking device represents the world’s first dual chamber leadless pacemaker, specifically designed to treat individuals with abnormal or slow heart rhythms—a condition affecting approximately 49 million people across the […]

Abbott launches GLP Systems Track lab automation system in US

Abbott launches GLP Systems Track lab automation system in US

Abbott has announced the launch of its innovative lab automation solution, GLP systems Track, which has recently received approval from the U.S. Food and Drug Administration (FDA). Now available in the United States, GLP systems Track is poised to transform laboratory operations, offering state-of-the-art features to support high-volume needs and maximize productivity in clinical labs. […]

Abbott secures Bigfoot Biomedical to boost diabetes care tech

Abbott secures Bigfoot Biomedical to boost diabetes care tech

Abbott has wrapped up the previously announced acquisition of Bigfoot Biomedical. The latter which is a Silicon Valley-based front-runner is celebrated for its revolutionary smart insulin management systems, notably enhancing diabetes care for patients worldwide. This acquisition propels Abbott’s standing in the diabetes domain, complementing its dominant FreeStyle Libre suite – a state-of-the-art continuous glucose […]

Abbott closes $890m acquisition of Cardiovascular Systems

Abbott closes $890m acquisition of Cardiovascular Systems

Abbott has closed the previously announced $890 million acquisition of Cardiovascular Systems, Inc. (CSI), which has developed an atherectomy system for the treatment of peripheral and coronary artery disease. As per the terms of the deal announced in February 2023, Cardiovascular Systems’ stockholders were offered $20 per share by Abbott. Cardiovascular Systems, which was trading […]

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in India. As per an agreement signed in late 2018, Abbott Healthcare had been promoting and distributing Dapagliflozin under the “Gledepa” brand name and the Dapagliflozin and Metformin combination under the […]

Abbott ID NOW COVID-19 test gets FDA nod to detect coronavirus in 5 mins

Abbott ID NOW COVID-19 test gets FDA nod to detect coronavirus in 5 mins

Abbott ID NOW COVID-19 test : Medical device company Abbott has been granted Emergency Use Authorization (EUA) for its five-minute novel coronavirus diagnostic test from the US Food and Drug Administration (FDA). The company has launched the coronavirus detection test following the FDA approval. According to Abbott, the ID NOW platform is the fastest available […]

CATALYST clinical trial : FDA approves Abbott’s trial of Amplatzer Amulet device in AF

CATALYST clinical trial : FDA approves Abbott’s trial of Amplatzer Amulet device in AF

Abbott has been granted approval from the US Food and Drug Administration (FDA) for the CATALYST clinical trial to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation (AF). According to the US medical device company, the CATALYST trial is the first-ever clinical trial that will compare the effectiveness of a […]